Shares of Rockwell Medical Inc. (NASDAQ:RMTI) fell 3.1% during trading on Monday . The company traded as low as $7.71 and last traded at $7.73, with a volume of 84,626 shares traded. The stock had previously closed at $7.98.

A number of brokerages have commented on RMTI. Morgan Stanley restated a “sell” rating on shares of Rockwell Medical in a research report on Wednesday, April 6th. Zacks Investment Research upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Friday, May 13th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. Rockwell Medical currently has an average rating of “Hold” and an average price target of $10.17.

The firm’s market capitalization is $397.78 million. The stock has a 50 day moving average of $8.06 and a 200-day moving average of $7.79.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $13.63 million for the quarter, compared to analyst estimates of $15.25 million. During the same period in the previous year, the company posted ($0.07) earnings per share. The firm’s revenue was down 1.8% on a year-over-year basis. On average, equities analysts forecast that Rockwell Medical Inc. will post ($0.27) EPS for the current fiscal year.

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.